ArticleJournal of hazardous materials2026
The cannabinoid receptor 2 is an in vivo receptor of bisphenol A during bone formation.
Article in Journal of hazardous materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Osteoporosis is a bone disorder characterized by decreased bone mass and increased risk of fractures afffecting over 200 million people worldwide. Currently the causes of osteoporosis are not well understood preventing an effective treatment for this disease. However, exposure to a common class of xenoestrogens known as bisphenols has been linked to this disorder. Our findings demonstrate that exposure to Bisphenol A (BPA) and its proposed replacements, bisphenol S (BPS) and tetrabromobisphenol A (TBBPA), reduces osteoblast number and calcification at environmentally relevant doses during zebrafish development. Transcriptomic analysis of osteoblast cells sorted after BPA exposure, revealed that the endocannabinoid pathway is one of the primary pathways disrupted. Bone growth is connected to the endocannabinoid system through cannabinoid receptor 1 (CB1) and 2 (CB2). Pharmacological activation of this pathway, combined with bisphenol exposure, has additive effects that further reduces osteoblast numbers and bone calcification. Exposure of CB1 or CB2 loss-of-function zebrafish mutants to bisphenols revealed that only the loss of CB2 prevents bisphenol induced bone defects. Furthermore, molecular docking analysis predicted that BPA, BPS, and TBBPA bind to the CB2 receptor with high affinity. Collectively, our data identifies CB2 as a novel receptor for bisphenol-mediated induction of bone defects in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.